Please select your Region.
Please select your Region.
May 22, 2013
ARKRAY, Inc. (herein ARKRAY) has signed an agreement to begin joint research with a research institute (IBN) under the umbrella of Singapore’s Agency for Science, Technology and Research. This is ARKRAY’s first overseas R&D endeavour. With knowledge from our new research partner in Singapore, and ARKRAY’s business know-how and technology, we will cooperate from research all the way through to product development.
ARKRAY researchers will move out to IBN’s laboratory within Biopolis*2 and begin joint development. ARKRAY will make full use of the knowledge and experience of the excellent researchers IBN has drawn from around the world as well as the great research facilities and environment that Biopolis has to offer as we build on our global R&D functions. The joint development will begin with a focus on infectious disease testing- a field in high demand throughout Asia- and will work to build synergistic development projects and gradually expand our field of work.
ARKRAY is working to accelerate R&D to rapidly deliver new products that meet with global market needs and trends.
*1 IBN = Institute of Bioengineering and Nanotechnology
This is one organization under the umbrella of Singapore’s Agency for Science, Technology and Research (A-STAR) and specializes in the bio-engineering and nanotechnology fields. It is involved in research of advanced technology across many different medical fields.
*2 Biopolis
This is a cluster set up to around Singaporean Industry and public bio-medical research. To promote bio-medical research, it offers a range of infrastructure services such as lab equipment, diagnostic devices and meeting facilities required by bio research groups. 2000 researchers from 40 public and private research organizations are currently actively engaged in research there. Over the next four years, Biopolis’ aim is to become a bio-medical hub with 4,000 researchers.